# Rivaroxaban or Aspirin for Biological Aortic Prosthesis

> **NCT02974920** · PHASE4 · UNKNOWN · sponsor: **Christian Torp-Pedersen** · enrollment: 1000 (estimated)

## Conditions studied

- Aortic Stenosis
- Aortic Regurgitation
- Thrombosis

## Interventions

- **DRUG:** Rivaroxaban 10 MG
- **DRUG:** Aspirin

## Key facts

- **NCT ID:** NCT02974920
- **Lead sponsor:** Christian Torp-Pedersen
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-01-01
- **Primary completion:** 2022-11-01
- **Final completion:** 2022-11
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2018-06-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02974920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02974920, "Rivaroxaban or Aspirin for Biological Aortic Prosthesis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02974920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*